乳牛に対する新しい治療法は抗生物質耐性との闘いに役立つ可能性があることが研究で明らかになった(New treatment for dairy cows could help fight antibiotic resistance, study finds)

ad

2024-12-18 ペンシルベニア州立大学(PennState)

ペンシルベニア州立大学(Penn State)の研究者たちは、乳牛の一般的な子宮感染症である臨床的メトリティス(子宮内膜炎)に対する新たな治療法として、高濃度の糖溶液(デキストロース)の有効性を検証しました。研究の結果、軽度のメトリティスにおいて、デキストロースによる治療は従来の抗生物質治療と同等の臨床的治癒率を示しました。さらに、デキストロースは生殖器官内の微生物バランスに大きな影響を与えず、抗生物質の使用による微生物群集の撹乱を回避できる可能性があります。この発見は、抗生物質耐性の拡大を抑制し、有機酪農業界における治療オプションの拡充に寄与することが期待されます。この研究成果は、2024年12月18日に『Frontiers in Veterinary Science』誌に掲載されました。

<関連情報>

乳牛の臨床的子宮中隔炎の治療における全身性抗生物質の代替としての子宮内ブドウ糖の使用:マイクロバイオームの観点から
Use of intrauterine dextrose as an alternative to systemic antibiotics for treatment of clinical metritis in dairy cattle: a microbiome perspective

Jennine Lection,Emily Van Syoc,Asha Miles,Julia Hamilton,Marcela Martinez,Santiago Bas,Justin Silverman,Adrian Barragan,Erika Ganda
Frontiers in Veterinary Science  Published:16 December 2024
DOI:https://doi.org/10.3389/fvets.2024.1478288

乳牛に対する新しい治療法は抗生物質耐性との闘いに役立つ可能性があることが研究で明らかになった(New treatment for dairy cows could help fight antibiotic resistance, study finds)

Introduction: Clinical metritis (CM) has significant costs to dairy producers. Current treatment strategy involves systemic antibiotics; however, there is increasing concern about judicious antibiotic use. The study objective was to evaluate the effects of a non-antibiotic treatment vs. systemic antibiotic therapy on the vaginal discharge microbiome of dairy cows diagnosed with CM at 7 ± 3 DIM (days in milk). We hypothesize that both treatment methods will have a similar impact on the reproductive microbiome due to broad-spectrum bactericidal activity; therefore, there will not be significant differences amongst the microbiota after the completion of therapy.

Methods: Cows from a central Pennsylvania dairy were screened for CM at 7 ± 3 days DIM using a Metricheck™ device (n = 351). Cows with red-brown watery discharge were diagnosed with CM and eligible for enrollment. Eligible cows (n = 77) were blocked by parity and randomly allocated to one of two treatments starting on the day of diagnosis: (1) Intrauterine dextrose (DEX, n = 38): 1 l of an intrauterine 50% dextrose solution for 3 days, and (2) Systemic ceftiofur (CONV, n = 39): two injections of ceftiofur (6.6 mg/Kg of BW; Excede, Zoetis Inc.) 72 h apart. Cows were evaluated for clinical cure rate at 7 ± 3 and 14 ± 3 days post-diagnosis. Vaginal discharge samples were collected using the Metricheck™ at enrollment day [study day (sd) 0, pre-treatment], sd 7, and sd 14 for a subset of enrolled cows (DEX = 13, CONV = 14). Vaginal discharge samples were analyzed with 16S rRNA sequencing to evaluate changes in the microbiome between treatments.

Results: After treatment, there were only minor differences within the microbiome between the two treatments indicating the potential suitability of dextrose as an antibiotic-alternative treatment. Alpha diversity did not differ (Welch’s t-test) between the treatments at any of the time points. Beta diversity based on PERMANOVA analysis did differ between treatments at sd 0 (P = 0.014) and again at sd 14 (P = 0.028), but not at sd 7 (P = 0.261).

Discussion: While 16S rRNA analysis does not provide information on bacterial viability, the relative similarity of the microbiome between the two groups immediately following treatment might suggest that intrauterine dextrose could be utilized as an alternative treatment for CM.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました